Unlimited Bio has introduced a VEGF gene therapy originally approved in Russia and Ukraine for ischemia, now being repurposed as a longevity treatment.

The company operates within Honduras' Prospera special economic zone, leveraging regulatory advantages to develop longevity-focused gene therapies.

Unlimited Bio emphasizes safety and data collection, offering discounts for follow-up and planning placebo-controlled studies to gather real-world evidence.

The VEGF therapy is considered safe, with over 10,000 patients treated over 15 years, and is claimed to be more affordable than other regenerative options.

The company aims to conduct 100 clinical trials over the next decade, focusing on combining multiple therapies to fight aging, starting with VEGF gene therapy.

Future plans include combining VEGF with therapies like follistatin, Klotho, and BDNF to target physical, cognitive, and immune functions, creating a comprehensive anti-aging cocktail.

Interest in longevity treatments has surged following celebrity endorsements, such as Khloé Kardashian receiving VEGF therapy, which has increased demand and visibility.